Due to the COVID-19 outbreak, Evonik announced that its contract manufacturer had to shut down its production facilities. Both production and shipping of the amino acid ThreAMINO (L-threonine) are affected.
L-threonine is an essential amino acid that supports protein synthesis but cannot be created by the animal. ThreAMINO is produced in a fermentation process using high-potential microbial strains.
Evonik said limited stocks of materials are available, and the supply shortage affects all regions.
Dr. Emmanuel Auer, head of Evonik's animal nutrition business line, explained: “Regrettably, we are facing a supply shortage for ThreAMINO. We have, therefore, decided to send a force majeure notification to our customers with immediate effect, in accordance with our contracts. Meanwhile, we will try the utmost to mitigate this situation and re-establish supply to our customers as fast as possible.”
Evonik said it will keep its customers regularly informed as the situation develops.
Evonik is one of the world leaders in specialty chemicals and is active in more than 100 countries. The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to applications for everyday consumer goods as well as animal nutrition and health care.